Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins were measured in longitudinal plasma samples collected from 13 participants who received two doses of mRNA-1273 vaccine. Eleven of 13 participants showed detectable levels of SARS-CoV-2 protein as early as day 1 after first vaccine injection. Clearance of detectable SARS-CoV-2 protein correlated with production of immunoglobulin G (IgG) and immunoglobulin A (IgA).

Automated summary

The study found that most participants showed detectable levels of SARS-CoV-2 protein as early as day 1 after receiving the mRNA-1273 vaccine, and the clearance of detectable SARS-CoV-2 protein correlated with the production of immunoglobulin G (IgG) and immunoglobulin A (IgA).